A study of Rina-S for people with non-small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called adenocarcinoma (a specific kind of non-small cell lung cancer).
- Your cancer must have spread to other parts of the body or cannot be removed with surgery or radiation.
- Your cancer must have gotten worse after your most recent treatment.
- You must have tumors that can be measured on scans.
- You must be well enough to do daily activities (ECOG score of 0 or 1).
- You cannot have another active cancer, unless it's been cured or is very low risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
This trial tests a new oral drug, GFH276, in people with advanced lung cancer that has a change in a gene called RAS. The drug is designed to target cancers with this specific mutation, and the study aims to find out if it is safe and effective for patients who have not had prior treatment for their advanced disease.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This study tests a new drug called Rina-S in people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have spread or cannot be surgically removed. The drug is designed to help slow or stop cancer growth in people whose cancer has gotten worse despite recent treatment.
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.